猸愶笍猸愶笍猸愶笍猸愶笍猸愶笍 "A total no brainer"

猸愶笍猸愶笍猸愶笍猸愶笍猸愶笍 "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2)

Official Title: Survey on the Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis Followed in Cystic Fibrosis (CF) Center in France

Study ID: NCT03653377

Conditions

Mucoviscidosis

Study Description

Brief Summary: Background The main risk factor for cervical cancer is the infection by human papillomavirus (HPV). Vaccination against HPV, offered to all girls aged 11 to 14 is an effective method of prevention against cervical pathology. Despite this, vaccination coverage against HPV remains low in France. A proportion of women with cystic fibrosis may be involved in transplantation, a factor associated with a higher risk of HPV carriage and cervical pathology. An over-risk of cervical pathology would also be present in women with non-transplanted cystic fibrosis. Particular attention to vaccination should therefore be included in this population. Objectives of the study The main objective of the study is to estimate the frequency of HPV vaccination in young girls with CF over 9 years and followed in a pediatric CF center. The secondary objectives are to know: * The type of vaccine used (bivalent / quadrivalent / nonavalent) * The proportion of vaccinated girls with respect of the vaccination schedule (number of injections / spacing between doses) * Reasons for non-use of vaccination Study design The study will last 12 months. It is a cross-sectional, non-interventional, multicenter conducted by self-administered questionnaire. Population * young girls aged 9 years or older with Cystic fibrosis * Followed in a pediatric or mixed CF center in the France (Rhone-Alpes Auvergne Region and Ile de France Region) * With parents who did not object to participation in the study Number of subject: 62 patients Expected results * Knowledge of HPV vaccination coverage in young girls with CF. * Sensitization of patients, their parents and health professionals to HPV vaccination. Understand the barriers and reasons for refusing vaccination to promote actions to improve immunization coverage.

Detailed Description:

Eligibility

Minimum Age: 9 Years

Eligible Ages: CHILD, ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Service Mucoviscidose, Pneumologie, Bron, , France

H么pital d'Estaing, Clermont-Ferrand, , France

P么le Couple / Enfant, Grenoble, , France

CRCM, H么pital Robert Debr茅, Paris, , France

CRCM, H么pital Trousseau, Paris, , France

CRCM, Institut Necker Enfants Malade, Paris, , France

Centre de Ressources et de Comp茅tences de la Mucoviscidose Adultes, Pierre-B茅nite, , France

Contact Details

Name: Christine ROUSSET-JABLONSKI, MD

Affiliation: Hospices Civils de Lyon

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: